NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE CHART. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
Stocks highlighted in this watchlist include $FOLD, MBOT, NLNK, MNKD. Good luck.
News: (Benzinga) The company released encouraging clinical trial data. The company's therapy showed a greater improvement in muscle and lung function for people suffering from Pompe, a rare disease that causes progressive muscle weakness. Pompe remains a "significant" growth driver for Amicus, Leerink's Joseph Schwartz commented in a report. Additional clinical data which is expected to be reported at the World Muscle Society (Oct. 3 through Oct. 7) will also show a differentiated profile from other Pompe enzyme replacement therapies.
Benzinga's Schwartz maintains an Outperform rating on Amicus' stock with a price target boosted from $17 to $20.
Globally, the Company now has 23 patents which are already issued and an additional 13 patent applications pending worldwide. The Company’s patents cover its ViRob™ and TipCAT™ technology platforms.
Harel Gadot, Chief Executive Officer, President, and Chairman commented: “In addition to India, the TipCAT™ technology platform patent has already been granted in the largest markets such as the U.S., China, Europe and several other markets, which we believe continues to show the strength of our IP assets. With this specific IP, our objective is to leverage the TipCAT platform to develop multiple products that address serious unmet needs in multiple medical applications.”
After a massive increase in the stock price in early September, the stock has consolidated nicely and is now beginning to show a reversal. Interestingly enough, the stock price is rising in response to a secondary offering that ended up priced much better than anticipated. Instead of hammering the stock as expected, the pricing announcement has lifted it. The offering is expected to close on or about October 6, 2017, subject to satisfaction of customary closing conditions. So this should be a perefect time to enter.
On Monday, the biotechnology company announced that the US Food and Drug Administration (FDA) has approved an update to the Afrezza prescribing information to include new clinical data. The Afrezza (human insulin) inhalation powder is now approved by the FDA to improve glycemic control in adult patients with type 1 and type 2 diabetes mellitus. Currently, it is the only inhaled rapid-acting mealtime insulin available in the United States, according to the Company.
MNKD also said that it had successfully exchanged new common stock for outstanding warrants issued last year, cleaning up the company's capital structure and giving it more flexibility for future financial moves. Investors are excited about MannKind, and that's showing in its rapidly rising share price.